Alzheimer's disease remains one of the most challenging neurodegenerative disorders to treat, despite decades of research and investment in drug development. The Alzheimer's disease age of onset varies, but most cases are diagnosed in individuals over 65, with Alzheimer's by age showing an increasing prevalence among older populations. Understanding why Alzheimer's happens is key to developing...

The Medical Marijuana Market continues to grow, propelled by rising interest in its health benefits, advancements in cannabis research, and supportive legislative changes. As cannabis treatments gain recognition for their efficacy, the market’s dynamics are rapidly shifting. DelveInsight’s comprehensive market analysis sheds light on the trends, opportunities, and challenges shaping...

Menopause is a major hormonal transition that can affect cognitive function, prompting research into the connection between menopause and Alzheimer’s. As estrogen levels decrease during menopause, it’s believed that this hormonal shift contributes to cognitive decline and heightens the risk of developing Alzheimer’s disease. Higher Alzheimer’s Risk in Post-Menopausal...

  The Alzheimer's disease landscape is evolving rapidly, driven by the dual challenges of an aging population and the urgent need for novel therapies for Alzheimer's disease. As the number of people affected by Alzheimer's continues to rise globally, the disease is becoming one of the most significant health concerns of our time. The rising incidence of Alzheimer's and the escalating...

Alzheimer's disease, a progressive neurodegenerative disorder, has emerged as one of the most critical global health challenges, especially due to the rapidly aging population. The Alzheimer's disease therapeutics market is witnessing significant transformation, driven by both demographic changes and advancements in medical research. As the burden of Alzheimer's disease continues to increase,...